Histopathological evaluation of prostate biopsy in-patient with Prostate cancer in Benghazi Medical Center in the period between 2020-2023.
DOI:
https://doi.org/10.37376/benunivmedj.v2i2.7499Keywords:
prostate cancer, adenocarcinoma, PSA, Libyan males, Benghazi, histopathology.Abstract
Abstract This descriptive, cross-sectional study was conducted at Benghazi Medical Center (BMC), Benghazi, Libya. Data were collected from the medical records of 81 patients diagnosed with prostate cancer who were admitted to the oncology department between January 2020 and December 2023. The aim of this study was to describe the demographic, clinical, and histopathological characteristics of prostate cancer patients. Results: The mean age of the patients was 71.6 years, and 83% of cases occurred among those aged 71–80 years. Overall, 19.8% of patients were smokers. Nine patients (11.1%) had diabetes mellitus, one patient (1.2%) had hypertension, and approximately 84% reported no family history of prostate cancer. Histopathological examination revealed adenocarcinoma in different stages of differentiation, with acinar adenocarcinoma accounting for 95% of cases and ductal adenocarcinoma for 2.5%. Most adenocarcinoma cases presented as Grade I (44.4%), followed by Grades II and IV (17.3% each). Conclusion: The study demonstrated that most cases occurred in older patients and were diagnosed at an early stage. Acinar adenocarcinoma was the predominant histopathological type, and the low rate of metastasis suggests a favorable prognosis.References
Chen J, Zhang D, Yan W, Yang D, Shen B. Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. BioMed Res Int. 2013;2013:901578. doi:10.1155/2013/901578.
Hjelmborg, J. B., Scheike, T., Holst, K., Skytthe, A., Penney, K. L., Graff, R. E., Pukkala, E., Christensen, K., Adami, H. O., Holm, N. V., Nuttall, E., Hansen, S., Hartman, M., Czene, K., Harris, J. R., Kaprio, J., & Mucci, L. A. (2014). The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiology, Biomarkers & Prevention, 23(11), 2303–2310. https://doi.org/10.1158/1055-9965.EPI-13-0568
Termini D, Hartogh DJD, Jaglanian A, Tsiani E. Curcumin against prostate cancer: current evidence. Biomolecules. 2020;10(11):1536. doi:10.3390/biom10111536.
Wen S, Chang HC, Tian J, Shang Z, Niu Y, Chang C. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Am J Pathol. 2015;185(2):293-301. doi:10.1016/j.ajpath.2014.10.012.
Cittadini A, Isidori AM, Salzano A. Testosterone therapy and cardiovascular diseases. Cardiovasc Res. 2021;118(8):2039-2057. doi:10.1093/cvr/cvab241.
Mesci, A., Lucien, F., Huang, X., Wang, E. H., Shin, D., Meringer, M., Hoey, C., Ray, J., Boutros, P. C., Leong, H. S., & Liu, S. K. (2019). RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer. Journal of translational medicine, 17(1), 125. https://doi.org/10.1186/s12967-019-1878-3
Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019;6(2):129-136. doi:10.1016/j.ajur.2018.11.007
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs Part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106-119. doi:10.1016/j.eururo.2016.02.028.
Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69(3):428-435. doi:10.1016/j.eururo.2015.06.046.
Garalla HM, Darraz KMA, Essa MMA. A retroprospective clinicopathological study of prostatic lesions in surgical specimens. Libyan Int Med Univ J. 2022;7:51-56.
Elhony A, El Darat T, Elkawafi R, Ramse W, Alzaghad AI, Sheriff DS. Gross hematuria and prostatic cancer in Libyan patients. J Adv Med Pharm Sci. 2019;21(2):1-5. doi:10.9734/JAMPS/2019/v21i230141.
Alhdiri MA, Samat NA, Mohamed Z. Mapping Libya’s prostate cancer based on the SMR method: a geographical analysis. Geografia Online TM Malaysian J Soc Space. 2016;12(9):118-125.
Malak S. Natural human factors play in the incidence of malignant tumors in the north-west of Libya [dissertation]. Tripoli, Libya: University of Tripoli; 2013. [Arabic].
Huncharek M, Haddock S, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100(4):693-701. doi:10.2105/AJPH.2009.185256.
Kwabi-Addo, B., Wang, S., Chung, W., Jelinek, J., Patierno, S. R., Wang, B. D., Andrawis, R., Lee, N. H., Apprey, V., Issa, J. P., & Ittmann, M. (2010). Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clinical cancer research : an official journal of the American Association for Cancer Research, 16(14), 3539–3547. https://doi.org/10.1158/1078-0432.CCR-09-3342
Raphael JE, Ekeke N. Hypertension and type 2 diabetes mellitus as risk factors for prostate cancer patients in Southern Nigerians. Saudi J Biomed Res. 2022;7(2):101-106.
Hameed S, Malik A, Bilal S, Dogar SR, Aslam A. Pattern of prostatic disease: a histopathological survey. Prof Med J. 2010;17(4):573-577.
Issac A, Varughese A, Raghuveer C, Asha SPK, Abdul Majeed N, Rajan J. A clinicopathological analysis of 120 cases of prostate biopsies and their correlation with prostate specific antigen levels. Ann Pathol Lab Med. 2018;5(11):A882-A887. doi:10.21276/apalm.2237.
Martin, R. M., Turner, E. L., Young, G. J., Metcalfe, C., Walsh, E. I., Lane, J. A., Sterne, J. A. C., Noble, S., Holding, P., Ben-Shlomo, Y., Williams, N. J., Pashayan, N., Bui, M. N., Albertsen, P. C., Seibert, T. M., Zietman, A. L., Oxley, J., Adolfsson, J., Mason, M. D., Davey Smith, G., … CAP Trial Group (2024). Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial. JAMA, 331(17), 1460–1470. https://doi.org/10.1001/jama.2024.4011
Daher, M., Telvizian, T., Dagher, C., Abdul-Sater, Z., Massih, S. A., Chediak, A. E., Charafeddine, M., Shahait, M., Alameddine, R., Temraz, S., Geara, F., Youssef, B., El Hajj, A., Nasr, R., Wazzan, W., Bulbul, M., Khauli, R., Shamseddine, A., & Mukherji, D. (2021). High rates of advanced prostate cancer in the Middle East: Analysis from a tertiary care center. Urology annals, 13(4), 418–423. https://doi.org/10.4103/UA.UA_47_20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Benghazi University Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright©2024University of Benghazi.
This open Access article is Distributed under a CC BY-NC-ND 4.0 license
Copyright
